타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Methylprednisolone (Methylprednisolone) Prevail Therapeutics·Ann Arbor Stage IIB Hodgkin Lympho… 178 trials |
|---|---|
Overview Program | Methylprednisolone |
Overview Company | Prevail Therapeutics |
Overview Modality | ADC |
Overview Target | Ann Arbor Stage IIB Hodgkin Lymphoma |
Overview Indication | Parkinson Disease |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Editorial scope · limited data |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | deruxtecan plus sintilimab: a case report |
MoA Mechanism | Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the |
MoA Biomarker | biomarker analyses and regional guidelines, particularly from East Asia, were reviewed to examine the indicat |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Methylprednisolone (Methylprednisolone) Prevail Therapeutics·Ann Arbor Stage IIB Hodgkin Lympho… 178 trials |
|---|---|
Overview Program | Methylprednisolone |
Overview Company | Prevail Therapeutics |
Overview Modality | ADC |
Overview Target | Ann Arbor Stage IIB Hodgkin Lymphoma |
Overview Indication | Parkinson Disease |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Editorial scope · limited data |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | deruxtecan plus sintilimab: a case report |
MoA Mechanism | Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the |
MoA Biomarker | biomarker analyses and regional guidelines, particularly from East Asia, were reviewed to examine the indicat |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교